| Trial ID: | L0763 |
| Source ID: | NCT00817037
|
| Associated Drug: |
Sitaxsentan
|
| Title: |
Sitaxsentan in Proteinuric Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease|Proteinuria|Blood Pressure
|
| Interventions: |
DRUG: Sitaxsentan|DRUG: Nifedipine|DRUG: Placebo tablet
|
| Outcome Measures: |
Primary: The principal objective of this study is to evaluate whether sitaxsentan reduces proteinuria in people with chronic kidney disease., 6 Weeks | Secondary: Secondary objective of this study is to evaluate whether sitaxsentan reduces systemic blood pressure in people with chronic kidney disease., 6 weeks|Secondary objective is to determine whether sitaxsentan improves indices of arterial stiffness in people with chronic kidney disease, 6 weeks|Secondary objectives is to determine the safety of sitaxsentan in chronic kidney disease, 6 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Edinburgh | Collaborators: Encysive Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
27
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-07-14
|
| Completion Date: |
2009-07-07
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-07
|
| Locations: |
Clinical Research Centre, Western General Hospital, Edinburgh, Scotland, EH4 2XU, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00817037
|
